<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31657">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01739218</url>
  </required_header>
  <id_info>
    <org_study_id>ML28337</org_study_id>
    <secondary_id>2012-001144-22</secondary_id>
    <nct_id>NCT01739218</nct_id>
  </id_info>
  <brief_title>A Study of Avastin (Bevacizumab) in Neoadjuvant Therapy in Patients With FIGO Stage IIIC/IV Ovarian, Tubal or Peritoneal Cancer, Initially Unresectable</brief_title>
  <official_title>A Randomized, Open-label, Phase II Study Assessing the Efficacy and the Safety of Bevacizumab in Neoadjuvant Therapy in Patients With FIGO Stage IIIC/IV Ovarian, Tubal or Peritoneal Adenocarcinoma, Initially Unresectable.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <authority>France: ANSM - Agence Nationale de Sécurité du Médicament</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, open-label study will evaluate the efficacy and safety of neoadjuvant
      Avastin (bevacizumab) in patients with initially unresectable, FIGO stage IIIC/IV ovarian,
      tubal or peritoneal cancer. Patients will be randomized to receive 8 cycles of carboplatin
      plus paclitaxel with or without Avastin 15 mg/kg intravenously every 3 weeks in Cycles 1 to
      3 before surgery. All patients will receive Avastin 15 mg/kg intravenously every 3 weeks for
      Cycles 6 to 26. Anticipated time on study treatment is until disease progression or
      unacceptable toxicity occurs, for up to a maximum of 26 cycles.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Complete resection rate after interval debulking surgery (IDS), defined as complete removal of all macroscopic residual tumour at IDS (Completeness of Cytoreduction Score = 0)</measure>
    <time_frame>approximately 4 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate before IDS (neoadjuvant phase), assessed according to RECIST v1.1 criteria and/or CA-125 levels)</measure>
    <time_frame>approximately 4 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate after all courses of treatment (16 months following IDS)</measure>
    <time_frame>approximately 4 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>approximately 4 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>approximately 4 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab [Avastin]</intervention_name>
    <description>15 mg/kg iv every 3 weeks, Day 1 of Cycles 1-3</description>
    <arm_group_label>Neoadjuvant Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC 5 mg/mL/min iv every 3 weeks, Day 1 of Cycles 1-8</description>
    <arm_group_label>Neoadjuvant Bevacizumab</arm_group_label>
    <arm_group_label>Active Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>175 mg/m2 iv every 3 weeks, Day 1 of Cycles 1-4, and 175 mg/m2 every 3 weeks or 80 mg/m2 weekly Cycles 5-8</description>
    <arm_group_label>Neoadjuvant Bevacizumab</arm_group_label>
    <arm_group_label>Active Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab [Avastin]</intervention_name>
    <description>15 mg/kg iv every 3 weeks, Day 1 of Cycles 6-26</description>
    <arm_group_label>Neoadjuvant Bevacizumab</arm_group_label>
    <arm_group_label>Active Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult female patients, &gt;/= 18 years of age

          -  Histologically confirmed and documented high risk stage IIIC/IV epithelial ovarian
             carcinoma, fallopian tube carcinoma or primary peritoneal carcinoma

          -  Patients are required to be deemed by a surgeon experienced in the management of
             ovarian cancer not to be eligible for primary complete debulking surgery during a
             laparoscopic procedure

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2

          -  Life expectancy &gt;/= 3 months

          -  Eligible for carboplatin and paclitaxel chemotherapy in accordance with local
             standards

          -  Patient should be beneficiary of healthcare coverage under the social security system

        Exclusion Criteria:

          -  Non-epithelial ovarian cancer, ovarian tumour with low malignant potential, or
             mucinous and clear cell ovarian cancer

          -  Evidence of abdominal free air not explained by paracentesis or recent surgical
             procedure

          -  Previous systemic therapy for ovarian cancer

          -  Previous exposure to mouse CA-125 antibody

          -  Current or recent treatment (within 28 days prior to Day 1, Cycle 1) with another
             investigational drug or previous participation in this study

          -  Current or recent (within 10 days prior to first study drug dose) chronic daily
             treatment with aspirin (&gt;325 mg/day)

          -  Planned intraperitoneal cytotoxic chemotherapy

          -  Inadequate bone marrow, liver or renal function

          -  History of myocardial infarction, unstable angina, stroke or ischemic attack within 6
             months prior to Day 1, Cycle 1

          -  Uncontrolled hypertension

          -  Clinically significant (i.e. active) cardiovascular disease (e.g. NYHA Class II or
             greater congestive heart failure, aortic aneurism)

          -  Pre-existing peripheral neuropathy &gt;/= CTC Grade 2

          -  Known hypersensitivity to bevacizumab or its excipients, Chinese hamster ovary cell
             products or other recombinant humanized antibodies or to any planned chemotherapy

          -  Pregnant or lactating females

          -  History of other clinically active malignancy within 5 years of enrolment, except for
             tumours with a negligible risk for metastasis or death, such as adequately controlled
             basal-cell or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix
             or breast
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: ML28337 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. Only)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75231</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>St Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 26, 2014</lastchanged_date>
  <firstreceived_date>November 28, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
